Key result
Treatment with the transcatheter debridement device induced safe decalcification of pericardium-based scaffolds without any adverse inflammatory events in an in vitro model.
Why the study?
Alternative treatments are needed to delay aortic valve stenosis progression and avoid prosthetic valve implantation, with ultrasound decalcification offering a potential solution.
Does a transcatheter debridement device using low-intensity ultrasound shock waves induce safe decalcification in an in vitro model of calcificated valves?
Does a transcatheter debridement device using low-intensity ultrasound shock waves induce safe decalcification in an in vitro model of calcificated valves?
An innovative transcatheter debridement device using ultrasound shock waves demonstrated safe decalcification without adverse inflammatory events in an in vitro model of calcificated valves.
Hypothesis-generating for transcatheter ultrasound debridement in calcific valves; prospective human studies needed before clinical consideration.
Aortic valve stenosis has become the most common valvular disease in elderly patients. Several treatments are available such as surgical aortic valve replacement and transcatheter aortic valve implantation. To date, however, there is a need to discover alternative treatments that can delay the disease progression and, therefore, the implant of a prosthetic valve. In this regard, a decalcification procedure based on the use of ultrasonic waves could represent an innovative solution in transcatheter cardiovascular therapies. In this article, we describe an innovative transcatheter debridement device (TDD) that uses low-intensity ultrasound shock waves for calcium ablation from the native aortic valve and bioprosthetic valve. Mesenchymal stem cells were seeded onto pericardium-based scaffolds and committed into an osteogenic phenotype. After treatment with TDD, cell proliferation was analyzed, as well as lactate dehydrogenase release and cell morphology. The release of calcium and inflammation events were detected. The results confirmed that the TDD was able to induce a safe decalcification without any adverse inflammatory events.
No takes yet. Share an insight, caveat, or question.
Tiengo et al. (2022) studied Aortic valve stenosis. Transcatheter debridement device (TDD) using low-intensity ultrasound shock waves was evaluated on Cell proliferation, lactate dehydrogenase release, cell morphology, calcium release, and inflammation events. Treatment with the transcatheter debridement device induced safe decalcification of pericardium-based scaffolds without any adverse inflammatory events in an in vitro model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: